On May 11, 2025, former U.S. President Donald Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the United States by 30% to 80%. The initiative, known as the “Most Favored Nation” (MFN) policy, seeks to align U.S. drug prices with those of the lowest-paying countries globally. Trump stated that this measure would bring “fairness to America” and could lead to immediate price reductions. The policy revives a similar effort from his first term, which was previously blocked in court. While the announcement has garnered public support, it faces anticipated opposition from the pharmaceutical industry, which argues that such pricing strategies could hinder innovation and patient access to medications. Details regarding the implementation, including its impact on Medicare and Medicaid, remain to be clarified.

Sources